AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

4 stories found

A desk lamp lights sample tubes, a paper form and a stamp in a model pathology lab with a dark monitor.
SecurityUnited Kingdom+2 clusters01

If the lab goes offline, who gets the next blood test?

If a hospital's network fails on a Tuesday morning, the blood in a sample tube doesn't stop changing. Somebody has to know where to send it, how to mark it urgent and who will call the ward with the result. A hospital can bring a server back online without any of those things working yet. Yesterday we covered the National Cyber Security Centre's assessment that AI-powered malware is highly likely to feature in a ransomware attack on UK critical infrastructure by 2028. The agency's November 3 announcement is the same warning, not evidence of a second attack. Today there's a more useful question: what does continued service look like when the system that fails belongs to a supplier? Consider Synnovis. After ransomware disrupted the pathology provider in June 2024, the NHS made arrangements so urgent blood samples could still be processed. That did not mean normal care had resumed. NHS London later counted 10,152 postponed acute outpatient appointments and 1,710 postponed elective procedures at the two most affected trusts. Those are appointments and procedures, not a count of unique patients. The NHS account does not attribute the attack to AI.

4 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters02

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
A conventional microscope with a compact motorized stage scans a bone-marrow slide and routes candidate-cell evidence to a gloved clinical reviewer.
Social good & healthUnited States and Global+3 clusters03

A low-cost self-driving microscope screens bone marrow slides for acute leukemia

A Nature Communications study presents ALLocate, a low-cost AI-powered plugin that turns a conventional microscope into a self-driving screening system for acute leukemia. The system automatically selects useful bone-marrow regions, detects cells, and produces a slide-level result without a whole-slide scanner. Researchers trained and evaluated it with more than 11,000 annotated regions and 130,000 annotated cells, then used independent multi-institutional cohorts that included 165 physical bone-marrow smear slides. Reported performance exceeded 0.99 AUROC for region selection, reached 0.90 mean average precision for cell detection, and achieved 88 percent accuracy for diagnosis on glass slides. That combination could make automated screening more accessible where scanners and specialist expertise are scarce. It does not support an autonomous final diagnosis. An 88 percent result leaves clinically important errors, and the study does not erase the need for population-specific validation, slide-quality checks, calibration, human confirmation, and escalation to a pathologist. The strongest deployment is a lower-cost bridge to expertise, not a substitute for it.

5 min
Technical failuresGlobal+1 clusters04

TRUECAM uncertainty-aware cancer-diagnostics framework

Nature Biomedical Engineering published a lung-cancer pathology AI paper introducing TRUECAM, a framework that detects out-of-scope inputs, filters ambiguous regions, and uses conformal prediction to control error rates; the authors report gains in accuracy, robustness, interpretability, data efficiency, and fairness across datasets and foundation models. its significance is less “AI replaces diagnosis” than “AI deployment requires uncertainty, fairness, and error-control layers.”

2 min